Bioleaders Corporation - Asset Resilience Ratio

Latest as of December 2025: 0.48%

Bioleaders Corporation (142760) has an Asset Resilience Ratio of 0.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Bioleaders Corporation PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩206.04 Million
≈ $139.63K USD Cash + Short-term Investments

Total Assets

₩42.61 Billion
≈ $28.87 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Bioleaders Corporation's Asset Resilience Ratio has changed over time. See 142760 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Bioleaders Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Bioleaders Corporation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩206.04 Million 0.48%
Total Liquid Assets ₩206.04 Million 0.48%

Asset Resilience Insights

  • Limited Liquidity: Bioleaders Corporation maintains only 0.48% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Bioleaders Corporation Industry Peers by Asset Resilience Ratio

Compare Bioleaders Corporation's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
Biotechnology 11.64%
Amicus Therapeutics Inc
NASDAQ:FOLD
Biotechnology 8.37%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 82.25%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653
Biotechnology 56.48%
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
Biotechnology 9.82%

Annual Asset Resilience Ratio for Bioleaders Corporation (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Bioleaders Corporation.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.48% ₩206.04 Million
≈ $139.63K
₩42.61 Billion
≈ $28.87 Million
-54.04pp
2024-12-31 54.52% ₩33.94 Billion
≈ $23.00 Million
₩62.25 Billion
≈ $42.19 Million
+15.12pp
2023-12-31 39.41% ₩19.34 Billion
≈ $13.11 Million
₩49.07 Billion
≈ $33.26 Million
+17.25pp
2022-12-31 22.15% ₩32.88 Billion
≈ $22.28 Million
₩148.42 Billion
≈ $100.58 Million
-12.49pp
2021-12-31 34.64% ₩65.42 Billion
≈ $44.33 Million
₩188.85 Billion
≈ $127.98 Million
+12.71pp
2020-12-31 21.93% ₩41.81 Billion
≈ $28.34 Million
₩190.69 Billion
≈ $129.23 Million
-8.32pp
2019-12-31 30.25% ₩44.80 Billion
≈ $30.36 Million
₩148.11 Billion
≈ $100.37 Million
+3.65pp
2018-12-31 26.60% ₩40.77 Billion
≈ $27.63 Million
₩153.29 Billion
≈ $103.88 Million
-42.29pp
2017-12-31 68.88% ₩25.88 Billion
≈ $17.54 Million
₩37.58 Billion
≈ $25.46 Million
+6.92pp
2016-12-31 61.96% ₩13.39 Billion
≈ $9.08 Million
₩21.61 Billion
≈ $14.65 Million
--
pp = percentage points

About Bioleaders Corporation

KQ:142760 Korea Biotechnology
Market Cap
$14.16 Million
₩20.89 Billion KRW
Market Cap Rank
#26139 Global
#1907 in Korea
Share Price
₩535.00
Change (1 day)
-9.32%
52-Week Range
₩535.00 - ₩2170.00
All Time High
₩24990.00
About

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more